Jim Cramer on Structure Therapeutics: “I Don’t Want to Touch It”

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented:

“Oh, okay, so this is a, they have a deal with Roche, and therefore, I think it’s a legitimate idea, but, boy, the stock fully reflects that deal. I don’t want to touch it. Lilly is still the gold standard.”

Structure Therapeutics Inc. (NASDAQ:GPCR) develops oral small-molecule drugs to treat chronic conditions like obesity and pulmonary fibrosis.

While we acknowledge the risk and potential of GPCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GPCR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.